VolitionRx Limited (AMEX:VNRX) shares traded 11.69% higher at $1.72 on Wall Street last session.
In accordance with the data, 3 analysts cover VolitionRx Limited (AMEX:VNRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $5.00, we find $5.75. Given the previous closing price of $1.54, this indicates a potential upside of 273.38 percent. VNRX stock price is now -21.02% away from the 50-day moving average and -14.85% away from the 200-day moving average. The market capitalization of the company currently stands at $111.47M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 1 analysts and a buy by 2. Brokers who have rated the stock have averaged $5.58 as their price target over the next twelve months.
, while ‘Maxim Group’ rates the stock as ‘Buy’.
In other news, Innes Guy Archibald, Director bought 234,000 shares of the company’s stock on Feb 22. The stock was bought for $409,500 at an average price of $1.75. Upon completion of the transaction, the Director now directly owns 154,504 shares in the company, valued at $0.27 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 19, Chief Scientific Officer Micallef Jacob Vincent bought 25,000 shares of the business’s stock. A total of $57,500 was incurred on buying the stock at an average price of $2.30. This leaves the insider owning 188,392 shares of the company worth $0.32 million. Insiders disposed of 123,895 shares of company stock worth roughly $0.21 million over the past 1 year. A total of 10.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VNRX stock. A new stake in VolitionRx Limited shares was purchased by SPECTRUM ASSET MANAGEMENT, INC. (NB/CA) during the first quarter worth $96,000. CERITY PARTNERS LLC invested $65,000 in shares of VNRX during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in VolitionRx Limited valued at approximately $51,000. CREATIVE PLANNING acquired a new stake in VNRX for approximately $23,000. NEWEDGE ADVISORS, LLC purchased a new stake in VNRX valued at around $1,000 in the second quarter. In total, there are 36 active investors with 10.40% ownership of the company’s stock.
VolitionRx Limited (AMEX: VNRX) opened at $1.4400 on Thursday. During the past 12 months, VolitionRx Limited has had a low of $1.31 and a high of $3.30. As of last week, the company has a debt-to-equity ratio of 1.27, a current ratio of 1.00, and a quick ratio of 1.00. The fifty day moving average price for VNRX is $2.1778 and a two-hundred day moving average price translates $2.0201 for the stock.
The latest earnings results from VolitionRx Limited (AMEX: VNRX) was released for Sep, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$0.14, beating analysts’ expectations of -$0.15 by 0.01. This compares to -$0.15 EPS in the same period last year. The company reported revenue of $0.12 million for the quarter, compared to $14000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 757.14 percent. For the current quarter, analysts expect VNRX to generate $280k in revenue.
VolitionRx Limited(VNRX) Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
